RemeGen Co (FRA:REG) Buildings And Improvements: €196 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:REG RemeGen Co Ltd FRA:REG
48 GF Score
Price €8.00
GF Value €25.42
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is RemeGen Co Buildings And Improvements?

RemeGen Co FRA:REG -1.48% 48 Buildings And Improvements is €196 Mil as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 48/100 and a GF Value™ of €25.42 (Possible Value Trap). The stock has 7 warning signs investors should review.

RemeGen Co's quarterly buildings and improvements declined from Dec. 2024 (€208 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€196 Mil).

RemeGen Co's annual buildings and improvements increased from Dec. 2023 (€191 Mil) to Dec. 2024 (€208 Mil) but then declined from Dec. 2024 (€208 Mil) to Dec. 2025 (€196 Mil).

RemeGen Co Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Buildings And Improvements Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial 82.45 123.53 190.81 208.08 195.70

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 208.08 0.00 195.70 0.00
FRA:REG
48GF Score
RemeGen Co Ltd FRA:REG
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of €196 Mil mean?
RemeGen Co (FRA:REG) has a Buildings And Improvements of €196 Mil as of Dec. 2025. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on RemeGen Co and its competitors.
Is RemeGen Co's Buildings And Improvements too high?
RemeGen Co's current Buildings And Improvements is €196 Mil. Overall, RemeGen Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Buildings And Improvements compare to VRTX and REGN?
RemeGen Co's Buildings And Improvements of €196 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on RemeGen Co and its competitors. RemeGen Co's current Buildings And Improvements is €196 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €25.42, compared to a current price of €8.00 — trading 68.5% below its estimated fair value. The current Buildings And Improvements is €196 Mil. RemeGen Co's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Buildings And Improvements is €196 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €8.00 is trading 68.5% below its estimated GF Value™ of €25.42. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • Buildings And Improvements: €196 Mil
  • GF Value™: €25.42 vs. price of €8.00 (68.5% below fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
48GF Score

Get the complete analysis for FRA:REG

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.00
Price
€25.42
GF Value